Edwards Lifesciences announced that the U.S. Food and Drug Administration (FDA) has approved the Autus Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital… read more.
Johnson & Johnson announced new long-term follow-up data from the initial subgroup of cohort A in the Phase 2 CARTITUDE-2 study (N=20) showing that 50% of patients (10/20)… read more.
NICE(UK): Isatuximab plus pomalidomide and dexamethasone can be used as an option to treat relapsed and refractory multiple myeloma in adults if: i) they have had 3 previous… read more.
Mirum Pharmaceuticals, Inc. and Incyte announced that the FDA has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric… read more.
Johnson & Johnson announced new findings on IMAAVY (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) across 15 novel abstracts to be presented at the 2026 Myasthenia… read more.
Vanda Pharmaceuticals Inc. announced positive topline results from its pivotal Phase III study of Hetlioz (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Vanda intends… read more.
Bristol Myers Squibb announced that the FDA approved CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and… read more.
Eli Lilly and Company announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control… read more.
AbbVie announced that the FDA has approved JUVMO (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson’s disease, a progressive… read more.
JCR Pharmaceuticals Co., Ltd. announced that the Ministry of Health, Labour and Welfare of Japan granted orphan drug designation to givinostat, an investigational drug for the treatment of… read more.
Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of Voquezna (vonoprazan)… read more.
Merck, known as MSD outside of the United States and Canada, and Eisai announced the FDA has approved the dual oral regimen of WELIREG (belzutifan), Merck’s first-in-class oral… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
